valsartan has been researched along with Aging in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kario, K | 1 |
| Janić, M; Lunder, M; Novaković, S; Šabovič, M; Škerl, P | 1 |
| Bai, X; Chen, X; Jin, B; Li, X; Shan, H; Yu, K; Zhang, S; Zhao, X | 1 |
| Hasegawa, Y; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Ma, M; Maeda, M; Nakagawa, T; Ogawa, H; Sueta, D; Toyama, K; Uekawa, K; Waki, H | 1 |
| Janić, M; Lunder, M; Šabovič, M | 2 |
| Mookherjee, S; Safar, ME; Smulyan, H | 1 |
| Williams, B | 1 |
| Chang, F; Flavahan, NA; Flavahan, S | 1 |
| Cohen, DL; Townsend, RR | 1 |
| Janić, M; Jug, B; Lunder, M; Sabovič, M | 1 |
| Burrell, LM; Johnston, CI | 1 |
| Cardot, JM; Ezzet, F; Godbillon, J; Jaouen, A; Lloyd, P; Marfil, F; Sioufi, A | 1 |
6 review(s) available for valsartan and Aging
| Article | Year |
|---|---|
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Topics: Aged; Aging; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Stroke Volume; Systole; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age.
Topics: Aging; Animals; Antioxidants; Arteries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Valsartan; Vascular Stiffness | 2015 |
The two faces of hypertension: role of aortic stiffness.
Topics: Aging; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aorta; Arteriosclerosis; Biphenyl Compounds; Blood Pressure; Diastole; Drug Combinations; Humans; Hypertension; Microcirculation; Prevalence; Pulse Wave Analysis; Pyridines; Risk Factors; Systole; Tetrazoles; Thiazepines; Valsartan; Vascular Resistance; Vascular Stiffness | 2016 |
Vascular ageing and interventions: lessons and learnings.
Topics: Aging; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Biphenyl Compounds; Blood Pressure; Drug Combinations; Humans; Hypertension; Tetrazoles; Valsartan; Vascular Stiffness | 2016 |
Update on pathophysiology and treatment of hypertension in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antihypertensive Agents; Blood Pressure; Geriatric Assessment; Humans; Hypertension; Prevalence; Risk Factors; Tetrazoles; United States; Valine; Valsartan | 2011 |
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Imidazoles; Kidney Diseases; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1997 |
3 trial(s) available for valsartan and Aging
| Article | Year |
|---|---|
Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat "Aging-Related Disorders".
Topics: Adult; Aging; AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Female; Fluvastatin; Gene Expression; Glucuronidase; Humans; Klotho Proteins; Longevity; Male; Middle Aged; Neurodegenerative Diseases; Placebo Effect; Sirtuin 1; Telomerase; Valsartan | 2019 |
Reduction of age-associated arterial wall changes by low-dose valsartan.
Topics: Adult; Age Factors; Aging; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Brachial Artery; Carotid Artery, Common; Double-Blind Method; Heart Rate; Humans; Male; Pulse Wave Analysis; Slovenia; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography; Valine; Valsartan; Vascular Diseases; Vascular Stiffness; Vasodilation | 2012 |
The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
Topics: Adult; Aging; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Blood Flow Velocity; Brachial Artery; Carotid Arteries; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pulsatile Flow; Tetrazoles; Valine; Valsartan; Vascular Stiffness | 2012 |
4 other study(ies) available for valsartan and Aging
| Article | Year |
|---|---|
Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blotting, Western; Cells, Cultured; Endothelium, Vascular; Extracellular Signal-Regulated MAP Kinases; Immunoenzyme Techniques; Male; Phosphorylation; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2014 |
Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Autonomic Nervous System; Baroreflex; beta-Galactosidase; Blood Pressure; Drug Evaluation, Preclinical; Endothelium, Vascular; Hypertension; Imidazoles; Myocardium; NADPH Oxidases; NG-Nitroarginine Methyl Ester; Norepinephrine; Organ Size; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reflex, Abnormal; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2014 |
Local renin-angiotensin system mediates endothelial dilator dysfunction in aging arteries.
Topics: Adrenergic alpha-1 Receptor Agonists; Aging; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arteries; Endothelium, Vascular; Enzyme Inhibitors; Fumarates; Indoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phenylephrine; Rats; Rats, Inbred F344; Renin; Renin-Angiotensin System; Valsartan; Vasodilation | 2016 |
The effect of age on the pharmacokinetics of valsartan.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Antihypertensive Agents; Area Under Curve; Female; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1998 |